Switzerland: Noema Pharma closes Series B at CHF103m

Noema Pharma, a clinical-stage biotech company targeting debilitating central nervous system disorders, has closed an oversubscribed Series B financing round, raising CHF103m (US$112m) from new and existing investors.  The round was co-led by European healthcare focused investment firms Forbion and Jeito Capital. UPMC Enterprises and an additional new investor joined existing investors Sofinnova Partners, Polaris…

You must be a HMI Subscriber to view this content.

Subscribe Now »